



**June 14-17, 2017**  
**Lugano, Switzerland**



**14<sup>th</sup> International Conference on Malignant Lymphoma**

# 14-ICML




Printed by courtesy of



Organized in association with:  
**Foundation for the Research and Cure of Lymphoma in Ticino**  
and **International Extranodal Lymphoma Study Group - IELSG**

## INDEX

Acknowledgements	3
Onsite Contact Details and Information	4
14-ICML Locations	6
General Information	7
Marquee Parco Ciani	8
Villa Ciani	9
Il Ciani	9
Program at a Glance	10
Scientific Program	15
14-ICML Transport Service	37
14-ICML Contacts	38



**SAVE THE DATE!**

**15-ICML**

15<sup>th</sup> International Conference on Malignant Lymphoma

Palazzo dei Congressi  
Lugano (Switzerland)  
[www.lymphcon.ch](http://www.lymphcon.ch)

**SAVE THE DATE: June 18-22, 2019**

# ACKNOWLEDGEMENTS

## INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (ICML) PRESIDENT

F. Cavalli, Bellinzona (Switzerland)

## CHAIRMAN OF ICML LOCAL ORGANIZING COMMITTEE

M. Ghielmini, Bellinzona (Switzerland)

## ICML LOCAL ORGANIZING COMMITTEE

(based in Bellinzona, Switzerland)

F. Bertoni

A. Moccia

F. Peccatori - European School of Oncology  
(ESO) representative

D. Rossi

A. Stathis

G. Stüssi

E. Zucca

## PRESIDENT OF ICML ADVISORY BOARD

J.O. Armitage, Omaha, NE (USA)

## ICML ADVISORY BOARD

E. Campo, Barcelona (Spain)

B.D. Cheson, Washington, D.C. (USA)

N. Chiorazzi, Manhasset, NY (USA)

J.M. Connors, Vancouver, BC (Canada)

R. Dalla-Favera, New York, NY (USA)

S. Dirnhofer, Basel (Switzerland)

M. Dreyling, Munich (Germany)

A. Engert, Cologne (Germany)

M.F. Fey, Bern (Switzerland)

J.W. Friedberg, Rochester, NY (USA)

G. Gaidano, Novara (Italy)

R.D. Gascoyne, Vancouver, BC (Canada)

P. Gaulard, Créteil (France)

M.K. Gospodarowicz, Toronto, ON (Canada)

E.S. Jaffe, Bethesda, MD (USA)

P.W.M. Johnson, Southampton (UK)

R. Küppers, Essen (Germany)

J.P. Leonard, New York, NY (USA)

T.A. Lister, London (UK)

A.M. Melnick, New York, NY (USA)

K. Ohshima, Kurume (Japan)

A. Pavlovsky, Buenos Aires (Argentina)

M.A. Piris, Madrid (Spain)

S.V. Rajkumar, Rochester, MN (USA)

J.F. Seymour, Melbourne (Australia)

M.A. Shipp, Boston, MA (USA)

L. Specht, Copenhagen (Denmark)

C. Thieblemont, Paris (France)

K. Tobinai, Tokyo (Japan)

U. Vitolo, Turin (Italy)

A. Younes, New York, NY (USA)

W. Wössmann, Giessen (Germany)

## CONFERENCE SECRETARIAT AND LOCAL ORGANIZATION

C. Brentan, O. Lugli, C. Saporiti  
Bellinzona (Switzerland)

### The conference organizers wish to thank the following sponsors for their unrestricted financial support:

AbbVie, Inc.

Acerta Pharma

AstraZeneca

Bayer

Bristol-Myers Squibb

Celgene Corporation

Cell Medica

Celltrion Healthcare

Gilead Sciences

Incyte Corporation

Invivoscribe®

Janssen Pharmaceutical Companies  
of Johnson & Johnson

Kite Pharma

Med Tech Trading

MorphoSys

MSD

Mundipharma Medical Company

Novartis Pharmaceuticals Corporation

Pfizer Oncology

Roche

Sandoz

Seattle Genetics

Servier Oncology

Takeda Oncology

Teva Oncology

Vifor Pharma

### The conference organizers wish to thank the following contributors for their support:

American Association for Cancer Research – AACR  
City of Lugano

Comunità Tariffale Arcobaleno

European Canine Lymphoma Network

European School of Oncology – ESO

European Society for Medical Oncology – ESMO

European Society for Radiotherapy and Oncology  
– ESTRO

IBSA Foundation for Scientific Research

International Lymphoma Radiation Oncology Group  
- ILROG

Kompetenznetz Maligne Lymphome e.V. (KML)

Leukämiehilfe Rhein-Main g.e.V. - LHRM

Lymphoma Coalition

Schweizerische Patientenorganisation für

Lymphombetroffene und Angehörige - ho / noho

Swiss Cancer Research Foundation

Swiss International Air Lines Ltd

Ticino Tourism

Union of Chinese Lymphoma Investigators – UCLI

University of Lugano – USI

(Università della Svizzera Italiana)

## ONSITE CONTACT DETAILS AND INFORMATION

### 14-ICML Registration and Information Desk

Monday, June 12:	only by appointments, only for groups
Tuesday, June 13:	08:30 – 19:30
from Wednesday, June 14, to Friday, June 16:	07:30 – 19:00
Saturday, June 17:	07:30 – 12:00

### ■ Contacts during the Conference

**Cristiana Brentan**  
(scientific program and general information) Tel. +41 76 750 54 65  
cristiana.brentan@lymphcon.ch

**Orietta Lugli**  
(exhibition, satellite symposia,  
ancillary meetings) Tel. +41 79 800 24 45  
orietta.lugli@lymphcon.ch

**Chiara Saporiti**  
(registrations and accounting) Tel. +41 58 866 66 68  
registration@lymphcon.ch

Please consider that during the Conference days we will have few chances to check our messages: do not use e-mail for urgencies!

The following services will be available in Palazzo dei Congressi:

- Internet Corner, sponsored by Takeda Oncology
- Speaker Preview Center
- Transport Info Desk, for information on public transports and buses organized by 14-ICML Secretariat
- Currency exchange office (cash only) → the closest automatic cash dispensers / ATM are Cornè Bank, via Canova 16 and Banca Coop, viale Cattaneo 17A.

- Free refreshment points with water supply, in co-operation with



- Restrooms:

Palazzo dei Congressi

▶ Level -1

"Villa Ciani"

▶ Level -1

Il Ciani Building

▶ Groundfloor

Marquee Parco Ciani

Cinema Corso

Lugano University

We invite you to attend an AbbVie-sponsored satellite symposium at the 14th International Conference on Malignant Lymphoma (ICML)

# NOVEL TREATMENTS IN RELAPSED/ REFRACTORY CLL: PRESENT AND FUTURE

Room B,  
Palazzo dei Congressi,  
Wednesday,  
June 14, 2017  
19:00–21:00

Chaired by Ulrich Jäger,  
who will be joined  
by a renowned  
international faculty  
of Davide Rossi,  
Barbara Eichhorst and  
Véronique Leblond

This will be an engaging and informative discussion of current and future approaches in the treatment of relapsed/refractory CLL

## 14-ICML LOCATIONS



**Palazzo dei Congressi**  
 Piazza Indipendenza 4, 6900 Lugano  
 Tel. +41 58 866 66 30  
 Fax: +41 58 866 66 39  
 E-mail: info@luganoconventions.com

- ▶ Main Convention Centre, Scientific Sessions

**Cinema Corso**,  
 Via G. B. Pioda 4

- ▶ Parallel Scientific Sessions, Room A overflow area

**Lugano University**, Via G. Buffi 13  
 Aula Magna hall

- ▶ Parallel Scientific Sessions, Room A overflow area

**Lugano University**, Via G. Buffi 13  
 Auditorium hall

- ▶ Parallel Scientific Sessions

**"Marquee Parco Ciani"**  
 Lugano town park

- ▶ Poster Session, Room B overflow area, Exhibition Area

**Villa Ciani**  
 Lugano town park

- ▶ Hospitality Suites and Meeting Rooms, Press Room, Sit&Meet Area

**Il Ciani Building**  
 Viale C. Cattaneo 5

- ▶ Meeting Rooms, Sit&Meet Area

**Campo Marzio Parking**,  
 Via Campo Marzio

- ▶ 14-ICML transport parking

## ■ GENERAL INFORMATION

### ■ Certificate of attendance – Evaluation Form

14-ICML program is designated for a maximum of, or up to, 24 European CME credits (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

Certificate of Attendance can be obtained as of FRIDAY, June 16 returning the completed Evaluation Form.

14-ICML is an European Society for Medical Oncology - ESMO supported meeting and is accredited with 25 ESMO-MORA cat. 1 points.



14-ICML is supported by European School of Oncology – ESO.

ICML program is part of the Certificate of Competence in Lymphoma, a 1-year ECTS curriculum of studies academically recognized by Ulm University. For further information, please visit [www.eso.net](http://www.eso.net).

### ■ 14-ICML Educational Book

Articles of the Educational Symposia and Meet the Professor sessions are included in the 14-ICML Educational Book, supplement to “Hematological Oncology” and published by Wiley. The supplement is distributed to attendees on site and also available online at the ICML official website ([www.lymphcon.ch](http://www.lymphcon.ch)) and at the Wiley Online Library website (<http://onlinelibrary.wiley.com>).

### ■ 14-ICML Abstract Book

All selected abstracts are included in the 14-ICML Abstract Book, published by Wiley and available online at the ICML official website ([www.lymphcon.ch](http://www.lymphcon.ch)) and at the Wiley Online Library website (<http://onlinelibrary.wiley.com>).

### ■ Best Abstract Merit Award and Travel Grants

The Best Abstract Merit Award and three Travel Grants, sponsored by the Swiss Cancer Research Foundation, have been assigned to the following young investigators (less than 35 years), on the basis of the evaluation results:

- Paula Cramer, Cologne (Germany)
- Sarah Huet, Pierre Bénite (France)
- Angelo Fama, Rochester, MN (USA)
- Luca Frigeni, Pavia (Italy)

### ■ Insurance

The 14-ICML Organizers bear no responsibility for untoward events in connection with, before, during and after the congress. Participants are strongly advised to take out their own personal and travel insurance coverage.


**NB:** charge of replacement of lost badge: CHF 100.

**krebsforschung schweiz**  
recherche suisse contre le cancer  
ricerca svizzera contro il cancro  
**swiss cancer research**

# MARQUE PARCO CIANI

Poster Session  
Room B Overflow Area  
Exhibition Area  
Coffee and Lunch Area

Lugano Lake



## ■ Opening hours:

Wednesday June 14	08:30 – 18:30
Thursday June 15	08:30 – 18:30
Friday June 16	08:30 – 18:30



## VILLA CIANI

Meeting Rooms  
Press Room  
Sit&Meet Area

### ■ Opening hours:

from Tuesday, June 13 to Friday, June 16 from 08:00 to 20:00

### ■ Ground Floor

Hospitality Suite nr 1	MUNDIPHARMA MEDICAL COMPANY
Business Centre nr 2 & 3	TAKEDA ONCOLOGY
Hospitality Suite nr 4 & 5	GILEAD SCIENCES
Meeting Room nr 6	BAYER

### ■ First Floor

Business Centre nr 7 & 8	CELGENE CORPORATION
--------------------------	---------------------

### ■ Second Floor

Meeting Room nr 9	KOMPETENZNETZ MALIGNEN LYMPHOME E.V. (KML)
Meeting Room nr 10	ROCHE
ICML Press Room	
Sit&Meet Area	

## IL CIANI BUILDING

Meeting Rooms  
Sit&Meet Area

### ■ Opening hours:

from Tuesday, June 13 to Friday, June 16 from 07:00 to 21:00  
Saturday, June 17 from 07:00 to 18:00

Meeting Room nr 1	GILEAD SCIENCES
Meeting Room nr 2 & 3	CELGENE CORPORATION
Meeting Room nr 4	MSD
Meeting Room nr 5	ACERTA PHARMA – ASTRA ZENECA
Meeting Room nr 6	INCYTE CORPORATION
Meeting Room nr 7	ABBVIE, INC.



**Complimentary internet wi-fi access is available for conference delegates throughout the venue.**

To access wi-fi, please use the following information:  
network name (SSID): 14-ICML  
password (PSK): Lugano2017

*Please note that wi-fi connection speed and performance depend on number of simultaneous accesses.*

The 14-ICML Application is available thanks to  AstraZeneca  Acerta Pharma  
It can be downloaded from the Apple App Store or Google Play.

# PROGRAM AT A GLANCE

TUESDAY, JUNE 13

	PCL ground floor Room A	PCL first floor Room B I	PCL first floor Room B II	Auditorium Lugano University	Aula Magna Lugano University			
7:15								
7:30								
7:45								
8:00				<p><b>CLOSED WORKSHOP</b>  <b>Design of clinical trials: Biological and clinical endpoints in the design of future clinical trials</b>                      (by invitation only)                      08:00-17:30                      Organized in co-operation with American Association for Cancer Research - AACR and European School of Oncology - ESO</p>				
8:15								
8:30								
8:45								
9:00								
9:15								
9:30								
9:45								
10:00								
10:15								
10:30								
10:45								
11:00								
11:15								
11:30								
11:45								
12:00		<p><b>CELLTRION HEALTHCARE</b>                      symposium room BI                      (12:00-14:00)</p>	<p><b>NOVARTIS PHARMACEUTICALS COMPANY</b>                      symposium room BII                      (12:00-14:00)</p>					
12:15								
12:30								
12:45								
13:00								
13:15								
13:30								
13:45								
14:00								
14:15								
14:30								
14:45								
15:00								
15:15					<p><b>WORKSHOP - Novel issues in the combined modality treatment of lymphomas</b>                      (open to all 14-ICML participants)                      15:00-17:30                      Organized by International Lymphoma Radiation Oncology Group - ILROG</p>			
15:30	<p><b>GILEAD SCIENCES</b>                      symposium room A                      (15:30-17:30)</p>	<p><b>BRISTOL-MYERS SQUIBB</b>                      symposium room BI                      (15:30-17:30)</p>	<p><b>SERVIER ONCOLOGY</b>                      symposium room BII                      (15:30-17:30)</p>					
15:45								
16:00								
16:15								
16:30								
16:45								
17:00								
17:15								
17:30								
17:45								
18:00								
18:15								
18:30								
18:45								
19:00	<p><b>ROCHE</b>                      symposium room A                      (19:00-21:00)</p>	<p><b>BAYER</b>                      symposium room BI                      (19:00-21:00)</p>	<p><b>TAKEDA ONCOLOGY</b>                      symposium room BII                      (19:00-21:00)</p>					
19:15								
19:30								
19:45								
20:00								
20:15								
20:30								
20:45								
21:00								
21:15								
21:30								

**WEDNESDAY, JUNE 14**

	PCL ground floor Room A	PCL first floor Room B	Marquee Parco Ciani	Cinema Corso	Auditorium Lugano University	Aula Magna Lugano University
7:15						
7:30						
7:45						
8:00						
8:15			POSTER SESSION SET UP (8:30-12:00)			
8:30	Meet the Professor: J.W. FRIEDBERG Chemotherapy-free treatment of indolent lymphomas (8:30-9:15)	Meet the Professor: L. QUINTANILLA-M. The 2016 updated WHO classification (8:30-9:15)	broadcasting of Meet the Professor: L. QUINTANILLA-M.	Meet the Professor: M. HALLEK Role and timing of new drugs in CLL (8:30-9:15)	Meet the Professor: J.G. GRIBBEN The role of stem cell transplant for lymphoma in 2017 (8:30-9:15)	Meet the Professor: M.F. FEY The costs of care in Haematological Cancers: health economic issues (8:30-9:15)
8:45						
9:00						
9:15						
9:30	Meet the Professor: P.W.M. JOHNSON Response-adapted therapy in HL (9:30-10:15)	Meet the Professor: K. TOBINAI Disease-oriented treatment of T-cell lymphomas (9:30-10:15)	broadcasting of Meet the Professor: K. TOBINAI	Meet the Professor: A. YOUNES Clinical applications of genome studies (9:30-10:15)	Meet the Professor: J.G. GRIBBEN The role of stem cell transplant for lymphoma in 2017 (9:30- 10:15)	Meet the Professor: M. RADERER The multiple facets of marginal zone lymphomas (9:30-10:15)
9:45						
10:00						
10:15			COFFEE (10:15-10:35)			
10:30	Educational Symposium AGGRESSIVE LYMPHOMAS (10:35-12:00) Room A	Educational Symposium IMMUNOTHERAPY IN LYMPHOMAS (10:35-12:00) Room B	broadcasting of Educational Symposium IMMUNOTHERAPY IN LYMPHOMAS (10:35-12:00)	broadcasting of Educational Symposium AGGRESSIVE LYMPHOMAS (10:35-12:00)		broadcasting of Educational symposium AGGRESSIVE LYMPHOMAS (10:35-12:00)
10:45						
11:00						
11:15						
11:30						
11:45						
12:00			LUNCH TIME and POSTER VIEWING			
12:15			Poster Session: 12:00-18:30			
12:30						
12:45						
13:00	OPENING OF THE CONFERENCE HENRY KAPLAN MEMORIAL LECTURE (13:00-14:00) room A - B - Marquee		broadcasting of Opening of the Conference Kaplan Lecture (13:00-14:00)	broadcasting of Opening of the Conference Kaplan Lecture (13:00-14:00)		broadcasting of Opening of the Conference Kaplan Lecture (13:00-14:00)
13:15						
13:30						
13:45						
14:00	PLENARY SESSION (14:00-15:15) room A - B - Marquee		broadcasting of PLENARY SESSION: (14:00-15:15)	broadcasting of PLENARY SESSION: (14:00-15:15)		broadcasting of PLENARY SESSION (14:00-15:15)
14:15						
14:30						
14:45						
15:00						
15:15						
15:30			COFFEE (15:15-15:40)	COFFEE (15:15-15:40)		COFFEE (15:15-15:40)
15:45						
16:00	AACR-ICML JOINT SESSION - CANCER IMMUNOTHERAPY (15:40-16:40) room A - B - Marquee		broadcasting of AACR-ICML Joint Session (15:40-16:40)	broadcasting of AACR-ICML Joint Session (15:40-16:40)		broadcasting of AACR-ICML Joint Session (15:40-16:40)
16:15						
16:30						
16:45						
17:00	"Focus on..." session CLASSICAL THERAPIES FOR FL (17:00-18:00)	"Focus on..." session PET/CT: VISUAL ASSESSMENT AND BEYOND (17:00-18:00)	broadcasting of "Focus on..." session room B (17:00-18:00)	"Focus on..." session CLINICO-PATHOLOGICAL CORRELATIONS (17:00-18:00)	"Focus on..." session NOVEL ANTI-LYMPHOMA DRUGS (17:00-18:00)	"Focus on..." session CHEMOTHERAPY-FREE COMBINATIONS (17:00-18:00)
17:15						
17:30						
17:45						
18:00						
18:15						
18:30						
18:45						
19:00	JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON symposium room A (19:00-21:00)	ABBVIE, INC. symposium room B (19:00-21:00)				
19:15						
19:30						
19:45						
20:00						
20:15						
20:30						
20:45						
21:00						
21:15						
21:30						

**THURSDAY, JUNE 15**

	PCL ground floor Room A	PCL first floor Room B	Marquee Parco Ciani	Cinema Corso	Auditorium Lugano University	Aula Magna Lugano University
7:15						
7:30						
7:45			<b>POSTER SESSION</b> (from 8:30 to 18:30)			
8:00	Meet the Professor: C. THIEBLEMONT	Meet the Professor: A. YOUNES	broadcasting of Meet the Professor: A. YOUNES	Meet the Professor: P.W.M. JOHNSON	Meet the Professor: L. BRUGERES & F. DAMORE	Meet the Professor: J.W. FRIEDBERG
8:15	Management of aggressive lymphomas in the very elderly patients (8:00-8:45)	Clinical applications of genome studies (8:00-8:45)		Response-adapted therapy in HL (8:00-8:45)	ALCL AND PTCL: what can pediatric and adult oncologists learn from each other? (8:00-8:45)	Chemotherapy-free treatment of indolent lymphomas (8:00-8:45)
8:30						
8:45						
9:00						
9:15	Clinical case discussion: HODGKIN LYMPHOMA (09:00-10:30)	<b>SESSION 1 LYMPHOMA BIOLOGY</b> (9:00-10:30) Room B - Marquee	broadcasting of SESSION 1 LYMPHOMA BIOLOGY (9:00-10:30)	Clinical case discussion: T-CELL LYMPHOMAS (09:00-10:30)	Clinical case discussion: PEDIATRIC AND ADOLESCENT LYMPHOMAS (09:00-10:30)	Clinical case discussion: RADIOTHERAPY FOR LYMPHOMAS (09:00-10:30)
9:30						
9:45						
10:00						
10:15						
10:30			COFFEE (10:30-11:00)			
10:45						
11:00	<b>SESSION 2 - PRIMARY MEDIASTINAL B-CELL LYMPHOMA</b> (11:00-12:00) Room A - B - Marquee Cinema Corso - Aula Magna		broadcasting of SESSION 2 PRIMARY MEDIASTINAL B-CELL LYMPHOMA (11:00-12:00)	broadcasting of SESSION 2 PRIMARY MEDIASTINAL B-CELL LYMPHOMA (11:00-12:00)		broadcasting of SESSION 2 PRIMARY MEDIASTINAL B-CELL LYMPHOMA (11:00-12:00)
11:15						
11:30						
11:45						
12:00						
12:15			<b>LUNCH TIME AND POSTER VIEWING</b>			
12:30			Poster Session: 8:30-18:30			
12:45						
13:00	<b>GIANNI BONADONNA MEMORIAL LECTURE</b> (13:00-13:45) Room A - B - Marquee Cinema Corso - Aula Magna		broadcasting of GIANNI BONADONNA LECTURE (13:00-13:45)	broadcasting of GIANNI BONADONNA LECTURE (13:00-13:45)		broadcasting of GIANNI BONADONNA LECTURE (13:00-13:45)
13:15						
13:30						
13:45						
14:00	<b>SESSION 3 - HODGKIN LYMPHOMA</b> (13:45-15:15) Room A - B - Marquee Cinema Corso - Aula Magna		broadcasting of SESSION 3 HODGKIN LYMPHOMA (13:45-15:15)	broadcasting of SESSION 3 HODGKIN LYMPHOMA (13:45-15:15)	Workshop - Contemporary lymphoma treatment: radiation therapy issues (open to all 14-ICML attendees) 13:15-16:45 Organized by International Lymphoma Radiation Oncology Group - ILROG	broadcasting of SESSION 3 HODGKIN LYMPHOMA (13:45-15:15)
14:15						
14:30						
14:45						
15:00						
15:15			COFFEE (15:15-15:30)	COFFEE (15:15-15:30)		COFFEE (15:15-15:30)
15:30	<b>SESSION 4 TARGETING THE BCR PATHWAYS</b> (15:30-17:00) Room A - Cinema Corso - Aula Magna	<b>SESSION 5 T-CELL LYMPHOMAS</b> (15:30-17:00) Room B - Marquee	broadcasting of SESSION 5 T-CELL LYMPHOMAS (15:30-17:00)	broadcasting of SESSION 4 TARGETING THE BCR PATHWAYS (15:30-17:00)		broadcasting of SESSION 4 TARGETING THE BCR PATHWAYS (15:30-17:00)
15:45						
16:00						
16:15						
16:30						
16:45						
17:00						
17:15	"Focus on..." session	"Focus on..." session	broadcasting of "Focus on..." session	"Focus on..." session	"Focus on..." session	"Focus on..." session
17:30	TARGETING CD30 IN HODGKIN LYMPHOMA (17:15-18:15)	NOVEL ANTI-LYMPHOMA STRATEGIES (17:15-18:15)	NOVEL ANTI-LYMPHOMA STRATEGIES (17:15-18:15)	CLINICO-GENETIC RISK MODELS (17:15-18:15)	ONGOING TRIALS (17:15-18:15)	LYMPHOMA IN THE ELDERLY (17:15-18:15)
17:45						
17:55						
18:00						
18:15						
18:30						
18:45						
19:00	<b>CELGENE symposium room A</b> (19:00-21:00)	<b>MUNDIPHARMA MEDICAL COMPANY - TEVA ONCOLOGY symposium room B</b> (19:00-21:00)				
19:15						
19:30						
19:45						
20:00						
20:15						
20:30						
20:45						
21:00						
21:15						
21:30						

**FRIDAY, JUNE 16**

	PCL ground floor Room A	PCL first floor Room B	PCL ground floor Room G	Marquee Parco Ciani	Cinema Corso	Auditorium Lugano University	Aula Magna Lugano University			
7:15										
7:30				<b>POSTER SESSION</b>						
7:45				(from 8:30 to 18:30)						
8:00	Meet the Professor: M. HALLEK	Meet the Professor: M. RADERER		broadcasting of	Meet the Professor: L. QUINTANILLA-M.	Meet the Professor: F.E. VAN LEEUWEN	Meet the Professor: C. THIEBLEMONT			
8:15	Role and timing of new drugs in CLL	The multiple facets of marginal zone lymphomas		Meet the Professor: M. RADERER	The 2016 updated WHO classification	Late sequelae in Hodgkin lymphoma survivors	Management of aggressive lymphomas in the very elderly patients			
8:30	(08:00-08:45)	(8:00-8:45)			(8:00-8:45)	(8:00-8:45)	(8:00-8:45)			
8:45										
9:00										
9:15	Clinical case discussion: <b>AGGRESSIVE LYMPHOMAS</b> (9:00-10:30)	<b>SESSION 6 LYMPHOMA GENOMICS</b> (9:00-10:30) Room B Marquee		broadcasting of	Clinical case discussion: <b>INDOLENT LYMPHOMAS</b> (09:00-10:30)	Clinical case discussion: <b>CLL</b> (09:00-10:30)	Clinical case discussion: <b>DIFFICULT PATHOLOGICAL CASES</b> (09:00-10:30)			
9:30				SESSION 6 LYMPHOMA GENOMICS (9:00-10:30)						
9:45										
10:00										
10:15										
10:30				<b>COFFEE</b> (10:30-10:50)						
10:45										
11:00	<b>SESSION 7 ADVANCES IN CLL</b> Room A - B - Marquee Cinema Corso - Aula Magna (10:50-12:05)			broadcasting of	broadcasting of	broadcasting of	broadcasting of			
11:15				SESSION 7 ADVANCES IN CLL				SESSION 7 ADVANCES IN CLL	SESSION 7 ADVANCES IN CLL	
11:30								IN CLL (10:50-12:05)	IN CLL (10:50-12:05)	IN CLL (10:50-12:05)
11:45										
12:00										
12:15			14-ICML Press Conference	<b>LUNCH TIME AND POSTER VIEWING</b> Poster Session: 8:30-18:30						
12:30										
12:45										
13:00	<b>JOHN ULTMANN MEMORIAL LECTURE</b> Room A - B - Marquee Cinema Corso - Aula Magna (13:00-13:45)			broadcasting of	broadcasting of		broadcasting of			
13:15				JOHN ULTMANN LECTURE				JOHN ULTMANN LECTURE	JOHN ULTMANN LECTURE	
13:30								(13:00-13:45)	(13:00-13:45)	(13:00-13:45)
13:45	<b>SESSION 8 FOLLICULAR LYMPHOMA</b> Room A - B - Marquee Cinema Corso (13:45-15:15)									
14:00				broadcasting of	broadcasting of	<b>IBSA FOUNDATION SPECIAL FORUM BASIC MECHANISMS OF CANCER IMMUNOTHERAPY</b> (open to all 14-ICML participants) 14:15-17:15 Organized by IBSA Foundation for Scientific Research pre-registration is appreciated at <a href="http://www.ibsafoundation.org">www.ibsafoundation.org</a> (free session)	<b>UCLI ICML JOINT SESSION</b> - NK/T-cell lymphoma (open to all 14-ICML attendees) 14:15-17:05 Organized in co-operation with Union of Chinese Lymphoma Investigators - UCLI			
14:15				SESSION 8 FOLLICULAR LYMPHOMA (13:45-15:15)				SESSION 8 FOLLICULAR LYMPHOMA (13:45-15:15)		
14:30										
14:45										
15:00										
15:15				<b>COFFEE</b> (15:15-15:35)	<b>COFFEE</b> (15:15-15:35)					
15:30	<b>DESIGN OF FUTURE CLINICAL TRIALS: REPORT OF THE 14-ICML WORKSHOP</b> (15:35-15:50)			broadcasting of	broadcasting of					
15:45				REPORT OF THE 14-ICML WORKSHOP (15:35-15:50)				REPORT OF THE 14-ICML WORKSHOP (15:35-15:50)		
16:00	<b>SESSION 9 AGGRESSIVE LYMPHOMAS</b> Room A - B Marquee - Cinema Corso (15:50-17:20)									
16:15				broadcasting of	broadcasting of					
16:30				SESSION 9 AGGRESSIVE LYMPHOMAS (15:50-17:20)				SESSION 9 AGGRESSIVE LYMPHOMAS (15:50-17:20)		
16:45										
17:00										
17:15										
17:30										
17:45										
18:00				<b>Farewell Aperitif</b> (17:30-18:45)						
18:15										
18:30	<b>IOSI - THE BIG DEBATE</b> symposium supported by Gilead Sciences Europe Ltd. room A (18:30-19:30)	<b>KITE PHARMA</b> symposium room B (18:45-20:45)								
18:45										
19:00										
19:15										
19:30										
19:45										
20:00										
20:15										
20:30										
20:45	<b>concert at LAC</b> 20:30-22:00									
21:00										
21:15										
21:30										
21:30										

**SATURDAY, JUNE 17**

	PCL ground floor Room A	PCL first floor Room B	Room156 Lugano University
7:15			
7:30			
7:45			
8:00			
8:15			
8:30	<b>SESSION 10 IMMUNOTHERAPIES (08:30-10:00)</b>	<b>SESSION 11 MANTLE CELL LYMPHOMA (08:30-10:00)</b>	<b>SPECIAL SESSION CONTOURING IN MODERN LYMPHOMA RADIOTHERAPY PLANNING (08:00-10:30)</b> compulsory pre-registration up to 30 attendees at registration@lymphcon.ch (fee CHF 50.-)
8:45			
9:00			
9:15			
9:30			
9:45			
10:00			
10:15	<b>SESSION 12 - MARGINAL ZONE LYMPHOMA</b>		
10:30	Room A - B		
10:45	(10:15-11:15)		
11:00			
11:15	<b>14-ICML HIGHLIGHTS</b>		
11:30	"Take Home Messages" (11:15-11:40)		
11:45			
12:00	<b>CLOSURE AND FAREWELL (11:40-11:50)</b>		
12:15			
12:30			
12:45			
13:00			
13:15			
13:30		<b>WORKSHOP NEW DEVELOPMENTS IN CANINE LYMPHOMA</b> (open to all 14-ICML attendees) 13:30-18:15 Organized by European Canine Lymphoma Network	
13:45			
14:00			
14:15			
14:30			
14:45			
15:00			
15:15			
15:30			
15:45			
16:00			
16:15			
16:30			
16:45			
17:00			
17:15			
17:30			
17:45			
18:00			
18:15			
18:30			
18:45			
19:00			
19:15			
19:30			
19:45			
20:00			
20:15			
20:30			
20:45			
21:00			
21:15			
21:30			

# CONFERENCE SCHEDULE



## ESO 2017 FULL IMMERSION COURSE ON LEUKAEMIA AND LYMPHOMA

Chairmen: J.O. Armitage (USA), M.F. Fey (Switzerland) and E. Zucca (Switzerland)

Hosting Chair: F. Cavalli (Switzerland)

Held in co-operation with the European School of Oncology - ESO

**Date: June 10 – 13, 2017**

**Location: Monte Verità, Ascona**

## Monday, June 12, 2017

09:00 – 17:45  
Room E

ESMIT/ESO CASE-BASED LEARNING COURSE ON [18F]FDG PET/CT IN THE MANAGEMENT OF LYMPHOMA

**Compulsory pre-registration. Registration form can be downloaded at [www.eanm.org](http://www.eanm.org) and sent to [esmit@eanm.org](mailto:esmit@eanm.org)**

## Tuesday, June 13, 2017

08:00 – 17:30  
Auditorium  
(Lugano  
University)

CLOSED WORKSHOP - DESIGN OF CLINICAL TRIALS: BIOLOGICAL AND CLINICAL ENDPOINTS IN THE DESIGN OF FUTURE CLINICAL TRIALS

Co-chairs: A. Younes, New York, NY (USA) and E. Zucca, Bellinzona (Switzerland)

Organized in co-operation with American Association for Cancer Research – AACR and European School of Oncology – ESO  
**by invitation only**

12:00 – 14:00  
Room BI

*2 parallel symposia*

CELLTRION HEALTHCARE

THE 1ST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE

Chair: C. Buske, Ulm (Germany)

Room BII

NOVARTIS PHARMACEUTICALS CORPORATION

CHALLENGES AND OPPORTUNITIES IN THE MANAGEMENT OF AGGRESSIVE

B CELL LYMPHOMAS

Chair: S.J. Schuster, Philadelphia, PA (USA)

15:00 – 17:30  
Aula Magna  
(Lugano  
University)

WORKSHOP - NOVEL ISSUES IN THE COMBINED MODALITY TREATMENT OF LYMPHOMAS

Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark) Organized by International Lymphoma Radiation Oncology Group - ILROG

**open to all 14-ICML attendees**

15:00

PART 1: IMMUNOMODULATORY TREATMENT IN THE COMBINED MODALITY SETTING

IMMUNOMODULATORY TREATMENT AND RADIATION THERAPY IN LYMPHOMAS

T.M. Illidge, Manchester (UK)

15:15

IMMUNOMODULATORY TREATMENT, ALONE OR IN COMBINATION WITH OTHER TREATMENT MODALITIES IN THE TREATMENT OF LYMPHOMAS

C. Moskowitz, New York, NY (USA)

15:30	GENERATING AN ABCOPAL EFFECT BY RADIOTHERAPY FOLLOWED BY CHECKPOINT INHIBITORS IN INDOLENT LYMPHOMAS M.L. Palomba, New York, NY (USA)
15:45	PANEL DISCUSSION T.M. Illidge, Manchester (UK), C. Moskowitz, New York, NY (USA), M.L. Palomba, New York, NY (USA), M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark)
16:00 - 16:30	<b>COFFEE BREAK</b> - inside Aula Magna (Lugano University) for workshop attendees
16:30	<b>PART 2: NK/T-CELL LYMPHOMAS, AN EMERGING LYMPHOMA TYPE WITH SPECIAL ISSUES</b> NK/T-CELL LYMPHOMAS IN ASIA. TREATMENT PRINCIPLES. WHAT RADIATION THERAPY? WHAT CHEMOTHERAPY REGIMEN? WHEN TO COMBINE AND WHEN TO USE SINGLE MODALITY? M. Oguchi, Tokyo (Japan)
16:45	NK/T-CELL LYMPHOMAS IN THE WESTERN WORLD. EXPERIENCE WITH COMBINED MODALITY TREATMENT AT MSKCC S.M. Horwitz, New York, NY (USA)
17:00	THE BEIJING EXPERIENCE WITH RADIATION ALONE Y.-X. Li, Beijing (China)
17:15	PANEL DISCUSSION M. Oguchi, Tokyo (Japan), S.M. Horwitz, New York, NY (USA), Y.-X. Li, Beijing (China), L. Specht, Copenhagen (Denmark) and M.K. Gospodarowicz, Toronto (Canada)
15:30 – 17:30	<i>3 parallel symposia</i>
Room A	GILEAD SCIENCES <b>ADVANCING PROGNOSTICATION AND TARGETED STRATEGIES IN CLL AND FL</b> Co-chairs: M. Ghielmini, Bellinzona (Switzerland) and M. Hallek, Cologne (Germany)
Room B I	BRISTOL-MYERS SQUIBB <b>IMMUNO-ONCOLOGY RESEARCH IN LYMPHOMA: PRESENT AND FUTURE</b> Chair: G. Collins, Oxford (UK)
Room B II	SERVIER ONCOLOGY <b>MANAGEMENT OF MULTIPLY RELAPSED AGGRESSIVE NHL: NEW PERSPECTIVES</b> Co-chairs: R. Pettengell, London (UK) and E. Van Den Neste, Brussels (Belgium)
19:00 – 21:00	<i>3 parallel symposia</i>
Room A	ROCHE <b>IMPROVING TREATMENT STRATEGIES FOR PATIENTS WITH FOLLICULAR LYMPHOMA: HOW TO TRANSLATE NOVEL STUDY DATA INTO CLINICAL PRACTICE</b> Chair: B.D. Cheson, Washington D.C. (USA)
Room B I	BAYER <b>SHIFTING PARADIGMS IN THE MANAGEMENT AND TREATMENT OF INDOLENT NHL</b> Co-chairs: M. Ghielmini, Bellinzona (Switzerland) and M. Dreyling, Munich (Germany)
Room B II	TAKEDA ONCOLOGY <b>TARGETING CD30 IN LYMPHOMA: A MARKER FOR CHANGE?</b> Co-chairs: A. Engert, Cologne (Germany) and K.J. Savage, Vancouver (Canada)



## Wednesday, June 14, 2017

08:30 – 12:00 Marquee		<b>POSTER SESSION SET UP</b>
08:30 – 09:15	Article number	<b>"MEET THE PROFESSOR" SESSIONS</b> 📺 <i>5 parallel sessions</i>
Room A	II	CHEMOTHERAPY-FREE TREATMENT OF INDOLENT LYMPHOMAS J.W. Friedberg, Rochester, NY (USA) <i>repeated on Thursday, June 15, in Aula Magna (Lugano University)</i>
Room B and Marquee	VI	THE 2016 UPDATED WHO CLASSIFICATION OF LYMPHOID NEOPLASIAS L. Quintanilla-Martinez, Tuebingen (Germany) <i>repeated on Friday, June 16 in Cinema Corso</i>
Cinema Corso	IV	ROLE AND TIMING OF NEW DRUGS IN CLL M. Hallek, Cologne (Germany) <i>repeated on Friday, June 16, in Room A</i>
Auditorium (Lugano University)	III	THE ROLE OF STEM CELL TRANSPLANT FOR LYMPHOMA IN 2017 J.G. Gribben, London (UK) <i>repeated today at 09:30 in Auditorium (Lugano University)</i>
Aula Magna (Lugano University)	I	THE COSTS OF CARE IN HAEMATOLOGICAL CANCERS: HEALTH ECONOMIC ISSUES M.F. Fey, Bern (Switzerland) <i>offered only once</i>
09:30 – 10:15		<i>5 parallel sessions</i>
Room A	V	RESPONSE-ADAPTED THERAPY IN HODGKIN LYMPHOMA P.W.M. Johnson, Southampton (UK) <i>repeated on Thursday, June 15, in Cinema Corso</i>
Room B and Marquee	IX	DISEASE-ORIENTED TREATMENT OF T-CELL LYMPHOMAS K. Tobinai, Tokyo (Japan) <i>offered only once</i>
Cinema Corso	XI	CLINICAL APPLICATIONS OF GENOME STUDIES A. Younes, New York, NY (USA) <i>repeated on Thursday, June 15, in Room B</i>
Auditorium (Lugano University)	III	THE ROLE OF STEM CELL TRANSPLANT FOR LYMPHOMA IN 2017 J.G. Gribben, London (UK)
Aula Magna (Lugano University)	VII	THE MULTIPLE FACETS OF MARGINAL ZONE LYMPHOMAS M. Raderer, Vienna (Austria) <i>repeated on Friday, June 16, in Room B</i>
10:15 – 10:35 Marquee		<b>COFFEE BREAK</b>
10:35 – 12:00		<b>EDUCATIONAL SYMPOSIA</b> 📺 <i>2 parallel sessions</i>
Room A, Cinema Corso and Aula Magna (Lugano University)		AGGRESSIVE LYMPHOMAS Chair: E. Campo, Barcelona (Spain)
	XIII	MOLECULAR GENETICS OF AGGRESSIVE B CELL LYMPHOMAS R. Dalla-Favera, New York, NY (USA)
	XIV	PATHOLOGY AND CLASSIFICATION OF AGGRESSIVE MATURE B-CELL LYMPHOMAS E. Campo, Barcelona (Spain)

Room B and Marquee	<p>XV TREATMENT OF AGGRESSIVE B-CELL LYMPHOMAS S.M. Smith, Chicago, IL (USA)</p> <p>IMMUNOTHERAPY IN LYMPHOMAS Chair: S.M. Ansell, Rochester, MN (USA)</p>
12:00 – 18:30	<p>XVI IMMUNOLOGY F. Caligaris-Cappio, Milan (Italy) CAR T-CELLS D.G. Maloney, Seattle, WA (USA) CHECKPOINT INHIBITORS S.M. Ansell, Rochester, MN (USA)</p> <p>Abstract number <b>POSTER SESSION</b> (printing and delivery of the posters sponsored by Takeda Oncology)</p> <p>140-163 PATHOLOGY AND BIOLOGY 164-177 HODGKIN LYMPHOMA 178-204 AGGRESSIVE LYMPHOMAS 205-214 MANTLE CELL LYMPHOMA 215-234 INDOLENT LYMPHOMAS 235-241 CLL 242-257 NK and T-CELL LYMPHOMAS 258-289 NEW DRUG DEVELOPMENT</p>
12:00 – 13:00 Marquee	<p><b>LUNCH TIME AND POSTER VIEWING</b></p>
13:00 – 14:00 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)	<p><b>OPENING OF THE CONFERENCE</b> 🎤 WELCOME AND INTRODUCTORY REMARKS F. Cavalli, Bellinzona (Switzerland)</p>
	<p><b>HENRY KAPLAN MEMORIAL LECTURE AND ICML PRIZE</b> 🎤 Laudatio: A. Lanzavecchia, Bellinzona (Switzerland)</p>
14:00 – 15:15 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)	<p>001 IMMUNOTHERAPY COMES OF AGE TO TREAT LYMPHOMAS R. Levy, Stanford, CA (USA)</p> <p><b>PLENARY SESSION</b> Co-chairs: J.M. Vose, Omaha, NE (USA) and J.W. Friedberg, Rochester, NY (USA)</p>
14:00	<p>004 INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS F. Morschhauser, Lille (France)</p>
14:15	<p>Discussant: T.E. Witzig, Rochester, MN (USA)</p>
14:25	<p>005 CRISPR-Cas9 GENETIC SCREENS UNCOVER A B CELL RECEPTOR-MYD88 SUPERPATHWAY IN DIFFUSE LARGE B CELL LYMPHOMA R.M. Young, Bethesda, MD (USA)</p>
14:40	<p>Discussant: R. Dalla-Favera, New York, NY (USA)</p>

14:50	006	BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG) P. Cramer, Cologne (Germany) <i>Best Abstract Merit Award, sponsored by Swiss Cancer League Foundation</i>
15:05		Discussant: D. Rossi, Bellinzona (Switzerland)
15:15 – 15:40		<b>COFFEE BREAK</b>
Marquee, Cinema Corso and Aula Magna (Lugano University)		
15:40 – 16:40		<b>ACR-ICML JOINT SESSION - CANCER IMMUNOTHERAPY</b> Co-chairs: F. Cavalli, Bellinzona (Switzerland) and M. Foti, Philadelphia, PA (USA)
Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)		
15:40	007	GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS S.J. Schuster, Philadelphia, PA (USA)
15:55	008	AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA-1 S.S. Neelapu, Houston, TX (USA)
16:10	009	WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM MALIGNANT MELANOMA? A.M.M. Eggermont, Villejuif (France)
16:25	010	WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM LUNG CANCER? R. Stahel, Zurich (Switzerland)
16:40 – 17:00		<b>BREAK</b>
17:00 – 18:00		<b>"FOCUS ON..." SESSIONS</b> <i>5 parallel sessions</i>
Room A		<b>CLASSICAL THERAPIES FOR FOLLICULAR LYMPHOMA</b> Chair: A.T. Lister, London (UK)
17:00	011	OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF <sup>18</sup> F-FDG PET-CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG J.L. Brady, London (UK)
17:10	012	CVP OR R-CVP GIVEN AFTER INVOLVED-FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I-II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL M.P. MacManus, Melbourne (Australia)
17:20	013	RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO E. Hoster, Munich (Germany)

17:30	014	DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST-AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12-YEAR FOLLOW-UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL R. Pettengell, London (UK)
17:40	015	LONG TERM RESULTS OF THE FOLLO5 RANDOMIZED STUDY COMPARING R-CVP WITH R-CHOP AND R-FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY S. Luminari, Reggio Emilia (Italy)
17:50	016	CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS C. Sarkozy, Pierre Bénite (France)
Room B and Marquee		<b>PET/CT: VISUAL ASSESSMENT AND BEYOND</b> Chair: B.D. Cheson, Washington D.C. (USA)
17:00	017	PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOR VOLUME (TMTV) FOR PATIENTS WITH EARLY STAGE HODGKIN LYMPHOMA ENROLLED IN THE STANDARD ARM OF THE H10 (EORTC/LYSA/FIL) TRIAL A. Cottreau, Paris (France)
17:10	018	BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET-ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE A.J. Moskowitz, New York, NY (USA)
17:20	019	CAN BASELINE PET-CT FEATURES PREDICT OUTCOMES IN ADVANCED HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033) L.C. Pike, London (UK)
17:30	020	CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL) L. Rigacci, Florence (Italy)
17:40	021	PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY J. Trotman, Sydney (Australia)
17:50	022	FDG-PET AS A BIOMARKER OF RESPONSE IN DLBCL: THE HOVON 84 STUDY EXPERIENCE C.N. Burggraaff, Amsterdam (The Netherlands)
Cinema Corso		<b>CLINICO-PATHOLOGICAL CORRELATIONS</b> Chair: E.S. Jaffe, Bethesda, MD (USA)
17:00	023	NON-MEDIASTINAL CASES OF GREY ZONE LYMPHOMA: A PATHOLOGICAL AND CLINICAL SERIES OF 17 CASES FROM THE LYSA C. Sarkozy, Pierre Bénite (France)
17:10	024	<i>FOXP1</i> EXPRESSION IS INVERSELY CORRELATED WITH <i>EZH2</i> MUTATION STATUS AND PREDICTS POOR FAILURE-FREE SURVIVAL IN FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB AND CHEMOTHERAPY A. Mottok, Vancouver (Canada)

17:20	025	ELEVATED EXPRESSION OF LAG3 IS ASSOCIATED WITH POOR OUTCOME IN PATIENTS WITH DLBCL TREATED WITH R-CHOP C. Keane, Woolloongabba (Australia)
17:30	026	CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY M. Klanova, Prague (Czech Republic)
17:40	027	NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A CELAC NETWORK STUDY M. Cheminant, Paris (France)
17:50	028	ADULT PATIENTS WITH CAEBV-LIKE FEATURES: A DISTINCT SUBTYPE OF EPSTEIN-BARR VIRUS POSITIVE T/NK-CELL LYMPHOPROLIFERATIVE DISORDER K. Kawamoto, Kurume (Japan)
Auditorium (Lugano University)		<b>NOVEL ANTI-LYMPHOMA DRUGS</b> Chair: T.E. Witzig, Rochester, MN (USA)
17:00	029	PHARMACOLOGICAL ACTIVITY OF CB-103 IN HAEMATOLOGICAL MALIGNANCIES – AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION D. Weber, Basel (Switzerland)
17:10	030	ANTI-TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B-CELL NON-HODGKIN LYMPHOMA P. Pérez-Galán, Barcelona (Spain)
17:20	031	A NEW BCL-2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST-IN-HUMAN STUDY S. Le Gouill, Nantes (France)
17:30	032	PHASE I STUDY OF IPH4102, ANTI-KIR3DL2 MAB, IN RELAPSED/REFRACTORY CUTANEOUS T-CELL LYMPHOMAS (CTCL): DOSE-ESCALATION SAFETY, BIOMARKER AND CLINICAL ACTIVITY RESULTS M. Bagot, Paris (France)
17:40	033	A PHASE 1 STUDY OF THE ANTI-CD37 ANTIBODY-DRUG CONJUGATE AGS67E IN ADVANCED LYMPHOID MALIGNANCIES. INTERIM RESULTS A. Sawas, New York, NY (USA)
17:50	034	FIRST CLINICAL RESULTS OF ADCT-402, A NOVEL PYRROLOBENZODIAZEPINE-BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B-CELL LINEAGE NHL B.S. Kahl, St. Louis, MO (USA)
Aula Magna (Lugano University)		<b>CHEMOTHERAPY-FREE COMBINATIONS</b> Chair: S.M. Smith, Chicago, IL (USA)
17:00	035	FINAL RESULTS OF CALGB 50803 (ALLIANCE): A PHASE 2 TRIAL OF LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA P. Martin, New York, NY (USA)

17:10	036	L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) – A SINGLE-ARM PHASE II STUDY G. Salles, Lyon (France)
17:20	037	A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B-CELL LYMPHOMA F. Morschhauser, Lille (France)
17:30	038	PHASE IB STUDY OF CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS (NHL) J.M. Michot, Villejuif (France)
17:40	039	PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA C. Batlevi, New York, NY (USA)
17:50	040	UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR-1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL M.S. Davids, Boston, MA (USA)
19:00 – 21:00		<i>2 parallel symposia</i>
Room A		JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON <b>CURRENT CONTROVERSIES IN B-CELL LYMPHOMAS: HOW TO MANAGE PATIENTS WITH HIGH UNMET NEEDS</b> Chair: M. Ghilmini, Bellinzona (Switzerland)
Room B		ABBVIE, INC. <b>NOVEL TREATMENTS IN RELAPSED/REFRACTORY CLL: PRESENT AND FUTURE</b> Chair: U. Jäger, Vienna (Austria)

## Thursday, June 15, 2017

08:00 – 08:45	Article number	<b>MEET THE PROFESSOR SESSIONS</b> 🗣️ <i>5 parallel sessions</i>
Room A	VIII	MANAGEMENT OF AGGRESSIVE LYMPHOMAS IN VERY ELDERLY PATIENTS C. Thieblemont, Paris (France) <i>repeated on Friday, June 16, in Aula Magna (Lugano University)</i>
Room B and Marquee	XI	CLINICAL APPLICATIONS OF GENOME STUDIES A. Younes, New York, NY (USA)
Cinema Corso	V	RESPONSE-ADAPTED THERAPY IN HODGKIN LYMPHOMA P.W.M. Johnson, Southampton (UK)
Auditorium (Lugano University)	XII	ALCL AND PTCL: WHAT CAN PEDIATRIC AND ADULT ONCOLOGISTS LEARN FROM EACH OTHER? L. Brugières, Villejuif (France) and F. D'Amore, Aarhus (Denmark) <i>offered only once</i>
Aula Magna (Lugano University)	II	CHEMOTHERAPY-FREE TREATMENT OF INDOLENT LYMPHOMAS J.W. Friedberg, Rochester, NY (USA)
08:30 – 18:30 Marquee		<b>POSTER SESSION</b>

09:00 – 10:30		<b>"CASE DISCUSSION" SESSIONS</b> California vs Germany <i>4 parallel sessions</i>
Room A		HODGKIN LYMPHOMA Chair: C. Moskowitz, New York, NY (USA) Discussants: R.H. Advani, Stanford vs P. Borchmann, Cologne
Cinema Corso		T-CELL LYMPHOMAS Chair: J.M. Vose, Omaha, NE (USA) Discussants: L.C. Pinter-Brown, Orange vs G. Wulf, Goettingen
Auditorium (Lugano University)		PEDIATRIC AND ADOLESCENT LYMPHOMAS Chair: W. Wössmann, Giessen (Germany) Discussants: C. Bollard, Washington, DC vs B. Burkhardt, Muenster
Aula Magna (Lugano University)		RADIOTHERAPY FOR LYMPHOMAS Chair: L. Specht, Copenhagen (Denmark) Discussants: R.T. Hoppe, Stanford vs G. Mikhaeel, London (UK)
09:00 – 10:30 Room B and Marquee	Abstract number	<b>SESSION 1 – LYMPHOMA BIOLOGY</b> Co-chairs: R. Küppers, Essen (Germany) and M.A. Shipp, Boston, MA (USA)
09:00	041	GB VIRUS-C (GBV-C) INFECTION AND RISK OF LYMPHOMA: A CASE-CONTROL STUDY FROM NORTH AMERICA A. Fama, Rochester, MN (USA)
09:15	042	DRUG PERTURBATION BASED STRATIFICATION OF LYMPHOPROLIFERATIVE DISORDERS S. Dietrich, Heidelberg (Germany)
09:30	043	ETS1 POSITIVELY REGULATES FAIM3 IN ACTIVATED B CELL-LIKE (ABC) DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) V. Priebe, Bellinzona (Switzerland)
09:45	044	<i>NOTCH1</i> MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A <i>MYC</i> -RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS F. Pozzo, Aviano (Italy)
10:00	045	ACTIVATION OF RHOA-VAV1 SIGNALING IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA M. Sakata-Yanagimoto, Ibaraki (Japan)
10:15	046	TARGETABLE FUSIONS OF THE FRK TYROSINE KINASE IN ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA R.L. Boddicker, Rochester, MN (USA)
10:30 – 11:00 Marquee		<b>COFFEE BREAK</b>
11:00 – 12:00 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)		<b>SESSION 2 – PRIMARY MEDIASTINAL B-CELL LYMPHOMA</b> Co-chairs: A.J. Davies, Southampton (UK) and G.S. Nowakowski, Rochester, MN (USA)
11:00	047	MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA USING FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE SPECIMENS – AN LLMPP PROJECT A. Mottok, Vancouver (Canada)

11:15	048	METABOLIC HETEROGENEITY OF BASELINE 18-FDG PET-CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA L. Ceriani, Bellinzona (Switzerland)
11:30	049	OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA TREATED WITH DOSE-ADJUSTED EPOCH-R THERAPY: A MULTICENTER RETROSPECTIVE ANALYSIS L.G. Roth, New York, NY (USA)
11:45	050	EFFICACY AND SAFETY OF PEMBROLIZUMAB IN RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (rrPMBCL): INTERIM ANALYSIS OF THE KEYNOTE-170 PHASE 2 TRIAL P.L. Zinzani, Bologna (Italy)
12:00 – 13:00 Marquee		<b>LUNCH TIME AND POSTER VIEWING</b> <i>from 12:30 to 13:00 authors in front of their poster for discussion with attendees</i>
13:00 – 13:45 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)		<b>GIANNI BONADONNA MEMORIAL LECTURE</b> 🎤 Chair: R. Dalla-Favera, New York, NY (USA) <i>sponsored by American Association for Cancer Research – AACR</i>
13:15 – 16:45 Auditorium (Lugano University)	002	GENETIC SIGNATURES AND TARGETABLE PATHWAYS IN LYMPHOID MALIGNANCIES M.A. Shipp, Boston, MA (USA)
13:15 13:30 13:45		<b>WORKSHOP - CONTEMPORARY LYMPHOMA TREATMENT: RADIATION THERAPY ISSUES</b> Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and J. Yahalom, New York, NY (USA) Organized by International Lymphoma Radiation Oncology Group – ILROG <b>open to all 14-ICML attendees</b>
14:00		MY INDICATIONS FOR RADIATION THERAPY IN THE PRIMARY TREATMENT OF HODGKIN AND NON HODGKIN LYMPHOMAS A.K. Ng, Boston, MA (USA) C. Thieblemont, Paris (France) U. Ricardi, Turin (Italy)
14:15 – 14:25		Case oriented discussion: A.K. Ng, Boston (USA), C. Thieblemont, Paris (France), U. Ricardi, Turin (Italy), J. Yahalom, New York, NY (USA) and M.K. Gospodarowicz, Toronto (Canada)
14:25 14:40 14:55		<b>BREAK</b>  MY INDICATIONS FOR RADIATION THERAPY IN RELAPSED/REFRACTORY HODGKIN AND NON HODGKIN LYMPHOMAS J. Yahalom, New York, NY (USA) G. Salles, Lyon (France) G. Mikhaeel, London (UK)
15:10		Case oriented discussion: J. Yahalom, New York, NY (USA), G. Salles, Lyon (France), G. Mikhaeel, London (UK) and M.K. Gospodarowicz, Toronto (Canada)
15:25 – 15:45		<b>COFFEE BREAK</b> - <i>inside Auditorium (Lugano University) for workshop attendees</i>
15:45		APPROACHES TO REDUCE LATE EFFECTS OF LYMPHOMA TREATMENT B.S. Dabaja, Houston, TX (USA): IS PROTON THERAPY THE ANSWER?



16:00		D. Hodgson, Toronto (Canada): STRATEGIES TO REDUCE THE RISK OF SECOND MALIGNANCIES
16:15		L. Specht, Copenhagen (Denmark): STRATEGIES TO REDUCE THE RISK OF CARDIOVASCULAR LATE EFFECTS
16:30		Discussion: B.S. Dabaja, Houston, TX (USA), D. Hodgson, Toronto (Canada), L. Specht, Copenhagen (Denmark), J. Yahalom, New York, NY (USA) and M.K. Gospodarowicz, Toronto (Canada)
13:45 – 15:15		<b>SESSION 3 – HODGKIN LYMPHOMA</b>
Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)		Co-chairs: V. Diehl, Cologne (Germany) and A. Pavlovsky, Buenos Aires (Argentina)
13:45	051	RESTORE & TARGET: A CONCEPTUALLY NOVEL TREATMENT APPROACH TO CLASSICAL HODGKIN'S LYMPHOMA C. Schmitt, Berlin (Germany)
14:00	052	GENOTYPING OF CLASSICAL HODGKIN LYMPHOMA ON THE LIQUID BIOPSY A. Bruscaggin, Bellinzona (Switzerland)
14:15	053	eBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM-PET-POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL P. Borchmann, Cologne (Germany)
14:30	054	RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER A NEGATIVE INTERIM PET SCAN (CRUK/07/033) J. Trotman, Concord (Australia)
14:45	055	BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI-PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (cHL) R. Chen, Duarte, CA (USA)
15:00	056	COMBINED RISK OF SECOND MALIGNANT NEOPLASMS AND CARDIOVASCULAR DISEASE IN LONG-TERM HODGKIN LYMPHOMA SURVIVORS B.M. Aleman, Amsterdam (The Netherlands)
15:15 – 15:30		<b>COFFEE BREAK</b>
Marquee, Cinema Corso and Aula Magna (Lugano University)		
15:30 – 17:00		<i>2 parallel sessions</i>
15:30 – 17:00		<b>SESSION 4 – TARGETING THE BCR PATHWAYS</b>
Room A, Cinema Corso and Aula Magna (Lugano University)		Co-chairs: J.F. Seymour, Melbourne (Australia) and C. Thieblemont, Paris (France)
15:30	057	CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM A PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA G. Lenz, Muenster (Germany)

15:45	058	DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA P.L. Zinzani, Bologna (Italy)
16:00	059	BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) J. Trotman, Concord (Australia)
16:15	060	IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO-RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END-POINT OF THE LOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK C. Soussain, Saint-Cloud (France)
16:30	061	TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF A PHASE 1 STUDY J. Kaplan, Chicago, IL (USA)
16:45	062	THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN A PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES P.A. Hamlin, Basking Ridge, NJ (USA)
15:30 – 17:00 Room B and Marquee		<b>SESSION 5 – T-CELL LYMPHOMAS</b> Co-chairs: K. Tobinai, Tokyo (Japan) and J.M. Vose, Omaha, NE (USA)
15:30	063	GENE EXPRESSION PROFILING USING A RTMLPA ASSAY ALLOWS FOR AN ACCURATE CLASSIFICATION OF PERIPHERAL T-CELL LYMPHOMA AND HIGHLIGHTS NOVEL SUBGROUPS WITHIN PTCLs-NOS P. Ruminy, Rouen (France)
15:45	064	CHOP VERSUS GEM-P IN THE FIRST-LINE TREATMENT OF T-CELL LYMPHOMA: INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO-T TRIAL M. Gleeson, Sutton (UK)
16:00	065	ROLE OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS: A PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS G. Fossard, Pierre Bénite (France)
16:15	066	BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION Y.H. Kim, Stanford, CA (USA)
16:30	067	IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT C.P. Fox, Nottingham (UK)
16:45	068	GAD-M REGIMEN FOR NEWLY DIAGNOSED EXTRANODAL NK/T CELL LYMPHOMA: ANALYSIS OF EFFICACY AND SAFETY FROM PHASE II STUDY (NCT 01991158) Z. Li, Guang Zhou (China)
17:00 -17:15		<b>BREAK</b>

17:15 – 18:15		<b>"FOCUS ON..." SESSIONS</b> <i>5 parallel sessions</i>
Room A		<b>TARGETING CD30 IN HODGKIN LYMPHOMA</b> Chair: A. Engert, Cologne (Germany)
17:15	069	RESULTS OF A PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY) A. Gibb, Manchester (UK)
17:25	070	BRENTUXIMAB VEDOTIN CONSOLIDATION TO REDUCE RADIATION USE IN PATIENTS WITH LIMITED STAGE NON-BULKY HODGKIN LYMPHOMA: AN UPDATE FROM A PHASE 2 CLINICAL TRIAL S.I. Park, Charlotte, NC (USA)
17:35	071	RESULTS OF A MULTICENTRE UK-WIDE STUDY EVALUATING THE EFFICACY OF BRENTUXIMAB VEDOTIN IN RELAPSED, REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN THE PRE-TRANSPLANT NAÏVE SETTING T.A. Eyre, Oxford (UK)
17:45	072	BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY A. Bazarbachi, Beirut (Lebanon)
17:55	073	SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412) C.S. Diefenbach, New York, NY (USA)
18:05	074	INTERIM RESULTS FROM A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA A.F. Herrera, Duarte, CA (USA)
Room B and Marquee		<b>NOVEL ANTI-LYMPHOMA STRATEGIES</b> Chair: P.W.M. Johnson, Southampton (UK)
17:15	075	CLARITHROMYCIN AS A "REPURPOSING DRUG" AGAINST LYMPHOMAS: SAFETY AND EFFICACY PROFILES IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL) A.J. Ferreri, Milan (Italy)
17:25	076	A PHASE 1 STUDY OF PRALATREXATE PLUS ROMIDEPSIN REVEALS MARKED ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL) J.E. Amengual, New York, NY (USA)
17:35	077	CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR-DLBCL) - OUTCOME OF IBRUTINIB + R-GDP J. Kuruvilla, Kingston (Canada)
17:45	078	EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL A. Pettitt, Liverpool (UK)

17:55	079	VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF A PHASE I STUDY L.J. Swinnen, Baltimore, MD (USA)
18:05	080	POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA H. Tilly, Rouen (France)
Cinema Corso		<b>CLINICO-GENETIC RISK MODELS</b> Chair: P. Gaulard, Créteil (France)
17:15	081	APPLICATION OF A GENE EXPRESSION-BASED MODEL IN COMBINATION WITH FDG-PET IMAGING TO PREDICT TREATMENT RESPONSE IN ADVANCED HODGKIN LYMPHOMA IN THE RATHL STUDY (CRUK/07/033) C.H. Burton, Leeds (UK)
17:25	082	THE 23-GENE GENE EXPRESSION-BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL D.W. Scott, Vancouver (Canada)
17:35	083	GENE MUTATIONS AND COPY NUMBER ALTERATIONS (CNA) PREDICT FOR EARLY FAILURE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-CHOP I. Dlouhy, Barcelona (Spain)
17:45	084	KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL S. Ferrero, Turin (Italy)
17:55	085	BASELINE CIRCULATING CELL-FREE DNA LOAD IS RELATED TO, BUT ADDS PROGNOSTIC VALUE TO METABOLIC TUMOR BURDEN MEASURED BY FDG PET/CT IN FOLLICULAR LYMPHOMA M.H. Delfau-Larue, Creteil (France)
18:05	086	EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL S. Huet, Pierre Bénite (France) <i>Travel Grant Winner (sponsored by Swiss Cancer Research Foundation)</i>
Auditorium (Lugano University)		<b>ONGOING TRIALS</b> Chair: M. Dreyling, Munich (Germany)
17:15	OT01	ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R-CHOP VS PLACEBO/R-CHOP IN UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING A. Chiappella, Turin (Italy)
17:25	OT02	PHASE II STUDY OF DURVALUMAB (ANTI-PD-L1) COMBINED WITH EITHER R-CHOP OR LENALIDOMIDE AND R-CHOP IN PREVIOUSLY UNTREATED, HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA U. Jäger, Vienna (Austria)

17:35	OT03	CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA L. Nayak, Boston, MA (USA)
17:45	OT04	MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND A RITUXIMAB-LENALIDOMIDE MAINTENANCE V. Ribrag, Villejuif (France)
17:55	OT05	PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL) C.S. Tam, Melbourne (Australia)
18:05	OT06	A HEAD-TO-HEAD PHASE 3 STUDY COMPARING BGB-3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA C. Buske, Ulm (Germany)
Aula Magna (Lugano University)		<b>LYMPHOMA IN THE ELDERLY</b> Chair: U. Vitolo, Turin (Italy)
17:15	087	HIGHER AGE IS ASSOCIATED WITH INCREASED MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA S. Alig, Munich (Germany)
17:25	088	LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE: A LYSA STUDY M.H. Delfau-Larue, Creteil (France)
17:35	089	CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP O. Al-Sawaf, Cologne (Germany)
17:45	090	UNMET MEDICAL NEEDS IN HODGKIN LYMPHOMA WITH SPECIAL FOCUS ON THE ELDERLY – A POPULATION-BASED STUDY OF PATIENTS DIAGNOSED IN SWEDEN 1973-2014 M. Björkholm, Stockholm (Sweden)
17:55	091	TREATMENT STRATEGIES AND OUTCOMES IN DIFFUSE LARGE B-CELL LYMPHOMA OF THE ELDERLY: A DANISH POPULATION-BASED COHORT STUDY OF 1,011 PATIENTS M.B. Juul, Odense (Denmark)
18:05	092	REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEALTH-RELATED QOL WITH MAINTENANCE LENALIDOMIDE VS PLACEBO IN ELDERLY DLBCL PATIENT RESPONDERS TO R-CHOP C. Thieblemont, Paris (France)
19:00 – 21:00		<i>2 parallel symposia</i>
Room A		CELGENE <b>MANAGEMENT OF B-CELL NON-HODGKIN LYMPHOMA: WHERE ARE WE NOW AND WHERE ARE WE GOING?</b> Chair: G. Salles, Lyon (France)
Room B		MUNDIPHARMA MEDICAL COMPANY - TEVA ONCOLOGY <b>CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?</b> Chair: M. Ghielmini, Bellinzona (Switzerland)

## Friday, June 16, 2017

08:00 – 08:45	Article number	<b>MEET THE PROFESSOR SESSIONS</b> 🗨️ <i>5 parallel sessions</i>
Room A	IV	ROLE AND TIMING OF NEW DRUGS IN CLL M. Hallek, Cologne (Germany)
Room B and Marquee	VII	THE MULTIPLE FACETS OF MARGINAL ZONE LYMPHOMAS M. Raderer, Vienna (Austria)
Cinema Corso	VI	THE 2016 UPDATED WHO CLASSIFICATION OF LYMPHOID NEOPLASIAS L. Quintanilla-Martinez, Tuebingen (Germany)
Auditorium (Lugano University)	X	LATE SEQUELAE IN HODGKIN LYMPHOMA SURVIVORS F.E. Van Leeuwen, Amsterdam (The Netherlands) <i>offered only once</i>
Aula Magna (Lugano University)	VIII	MANAGEMENT OF AGGRESSIVE LYMPHOMAS IN VERY ELDERLY PATIENTS C. Thieblemont, Paris (France)
08:30 – 18:30 Marquee		<b>POSTER SESSION</b>
09:00 – 10:30		<b>"CASE DISCUSSION" SESSIONS</b> California vs Germany <i>4 parallel sessions</i>
Room A		AGGRESSIVE LYMPHOMAS Chair: S. Le Gouill, Nantes (France) Discussants: S. De Vos, Santa Monica vs G. Lenz, Muenster
Cinema Corso		INDOLENT LYMPHOMAS Chair: A. Lopez-Guillermo, Barcelona (Spain) Discussants: T.J. Kipps, La Jolla vs M. Dreyling, Munich
Auditorium (Lugano University)		CLL Chair: J.G. Gribben, London (UK) Discussants: S.M. O'Brien, Orange vs S. Stilgenbauer, Ulm
Aula Magna (Lugano University)		DIFFICULT PATHOLOGICAL CASES Chair: M. Ghielmini, Bellinzona (Switzerland) Presenters: E. Campo, Barcelona (Spain), S. Dirnhofer, Basel (Switzerland), L. Quintanilla-Martinez, Tuebingen (Germany) Discussants: S.T. Rosen, Duarte vs U. Dührsen, Essen
09:00 – 10:30 Room B and Marquee		<b>SESSION 6 – LYMPHOMA GENOMICS</b> Co-chairs: A. Melnick, New York, NY (USA) and W.-L. Zhao, Shanghai (China)
09:00	093	A SINGLE-CELL BASED MODEL EXPLAINS PATTERNS OF CLONAL EVOLUTION IN PRIMARY AND RELAPSED FOLLICULAR LYMPHOMA M. Löffler, Leipzig (Germany)
09:15	094	FULL TRANSCRIPTOME SEQUENCING OF SORTED HODGKIN AND REED-STERNBERG CELLS REVEALS PLASMACYTIC DIFFERENTIATION: INSIGHTS INTO MECHANISMS OF ONCOGENESIS AND IMMUNE EVASION M. Roshal, New York, NY (USA)

09:30	095	PROFILING OF DNA METHYLATION IN EPIDEMIOLOGICAL AND CLINICAL SUBGROUPS OF BURKITT LYMPHOMA IN THE FRAMEWORK OF THE MMML: ICGC AND BLUEPRINT CONSORTIA R. Wagener, Ulm (Germany)
09:45	096	MUTATIONAL SIGNATURES IN GERMINAL CENTER DERIVED B-CELL LYMPHOMAS FROM ADULT PATIENTS ANALYZED IN THE ICGC MMML-SEQ CONSORTIUM D. Huebschmann, Heidelberg (Germany)
10:00	097	CROSS-PLATFORM VALIDATION OF GENE EXPRESSION PROFILING (GEP) BASED CELL OF ORIGIN (COO) CLASSIFICATION IN A CLINICAL LABORATORY SETTING S. Barrans, Leeds (UK)
10:15	098	THE LANDSCAPE OF SOMATIC MUTATIONS OF PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG-TYPE F. Jardin, Rouen (France)
10:30 – 10:50 Marquee		COFFEE BREAK
10:50 – 12:05 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)		SESSION 7 – ADVANCES IN CLL Co-chairs: N. Chiorazzi, Manhasset, NY (USA) and B. Eichhorst, Cologne (Germany)
10:50	099	INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49d: CLINICAL RELEVANCE E. Tissino, Aviano (Italy)
11:05	100	INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH-RISK PROGNOSTIC FACTORS T.J. Kipps, La Jolla, CA (USA)
11:20	101	UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY A. Mato, Philadelphia, PA (USA)
11:35	102	CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL L.J. Nastoupil, Houston, TX (USA)
11:50	103	SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB-3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) C.S. Tam, Melbourne (Australia)
12:05 – 13:00 Marquee		LUNCH TIME AND POSTER VIEWING <i>from 12:30 to 13:00 authors in front of their poster for discussion with attendees</i>

13:00 – 13:45 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)	003	<p><b>JOHN ULTMANN MEMORIAL LECTURE</b> 🎤 Chair: E. Campo, Barcelona (Spain) <i>sponsored by European School of Oncology – ESO</i></p> <p>GENOMES IN TRANSIT: WHAT MULTI-OMICS CAN TELL US ON LYMPHOMAS R. Siebert, Ulm (Germany)</p> <p><i>3 parallel sessions</i></p>
13:45 – 15:15 Room A, B, Marquee and Cinema Corso		<p><b>SESSION 8 – FOLLICULAR LYMPHOMA</b> Co-chairs: B.S. Kahl, St. Louis, MO (USA) and E. Kimby, Stockholm (Sweden)</p>
13:45	104	<p>GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA S. Huet, Pierre Bénite (France)</p>
14:00	105	<p>THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE M. Federico, Modena (Italy)</p>
14:15	106	<p>PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: A POOLED ANALYSIS FROM LYSA AND FIL TRIALS A. Cottreau, Paris (France)</p>
14:30	107	<p>IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN W. Hiddemann, Munich (Germany)</p>
14:45	108	<p>COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1) M. Dreyling, Munich (Germany)</p>
15:00	109	<p>HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN-LABEL, PHASE II STUDY L.J. Nastoupil, Houston, TX (USA)</p>
14:15 – 17:15 Auditorium (Lugano University)		<p><b>IBSA FOUNDATION SPECIAL FORUM - BASIC MECHANISMS OF CANCER IMMUNOTHERAPY</b> Chair: A. Alimonti, Bellinzona (Switzerland) Organized by IBSA Foundation for Scientific Research <b>open to all 14-ICML attendees, appreciated pre-registration at <a href="http://www.ibsafoundation.org">www.ibsafoundation.org</a> (free session)</b></p>
14:15		<p>WELCOME S. Misiti Lugano (Switzerland)</p>
14:20		<p>INTRODUCTION A. Alimonti, Bellinzona (Switzerland)</p>
14:30		<p>IMMUNOTHERAPY HAS COME OF AGE R. Levy, Stanford, CA (USA)</p>



15:00		IMMUNOGENIC CELL DEATH: EXPLAINING THE SUCCESS OF CANCER THERAPIES G. Kroemer, Paris (France)
15:30 – 16:00		<b>COFFEE BREAK</b> - inside Auditorium (Lugano University) for attendees
16:00		WHY THE IMMUNE RESPONSE IN LYMPHOMA IS INADEQUATE F. Caligaris-Cappio, Milan (Italy)
16:30		PRE-CLINICAL DEVELOPMENT OF NOVEL COMBINATORIAL THERAPIES AGAINST MYC/BCL2 DOUBLE-HIT LYMPHOMA B. Amati, Milan (Italy)
14:15 – 17:05	Aula Magna (Lugano University)	<b>UCLI-ICML JOINT SESSION - NATURAL KILLER / T-CELL (NK/T-CELL) LYMPHOMA</b> Co-chairs: J.M. Vose, Omaha, NE (USA), J. Zhu, Beijing (China) and Y.-K. Shi, Beijing (China) Organized in collaboration with Union of Chinese Lymphoma Investigators - UCLI
14:15	110	NON-CANONICAL ROLE OF EZH2 IN NK / T-CELL LYMPHOMA W.-J. Chng, Singapore (Singapore)
14:30	111	EBV-ASSOCIATED NODAL T AND NK-CELL LYMPHOMA SHOWS DISTINCT MOLECULAR SIGNATURE AND COPY NUMBER CHANGES W.-J. Chng, Singapore (Singapore)
14:45	112	NK/T-CELL LYMPHOMA: WHEN PATIENTS MEET OMICS W.-L. Zhao, Shanghai (China)
15:00	113	TREATMENT OF EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE (ENKTL) W.S. Kim, Seoul (South Korea)
15:15 – 15:35		<b>COFFEE BREAK</b> - inside Aula Magna (Lugano University) for attendees
15:35	114	FIRST-LINE L-ASPARAGINASE-BASED CHEMOTHERAPY PLUS RADIOTHERAPY IS ACTIVE IN STAGE I/II EXTRANODAL NK/T-CELL LYMPHOMA: RESULTS FROM PEKING UNIVERSITY CANCER HOSPITAL Y.-Q. Song, Beijing (China)
15:50	115	CURRENT TREATMENT FOR NK/T CELL LYMPHOMA: SUN YAT-SEN UNIVERSITY CANCER CENTER EXPERIENCE, CHINA H.-Q. Huang, Guangzhou (China)
16:05	116	MOLECULAR CHARACTERIZATION OF EXTRANODAL NATURAL KILLER (NK)/T-CELL LYMPHOMAS, NASAL TYPE FROM LATIN AMERICA L. Quintanilla-Martinez, Tuebingen (Germany)
16:20	117	NK/T-CELL LYMPHOMA, THE FRENCH EXPERIENCE A. Jaccard, Limoges (France)
16:35		COMMENTS M. Federico, Modena (Italy), W.-Q. Jiang, Guangzhou (China) and X.-P. Lu, Shenzhen (China)
15:15 – 15:35	Marquee and Cinema Corso	<b>COFFEE BREAK</b>

15:35 – 15:50 Room A, B, Marquee and Cinema Corso		DESIGN OF FUTURE CLINICAL TRIALS: REPORT OF THE 14-ICML WORKSHOP Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and E. Zucca, Bellinzona (Switzerland) A. Younes, New York, NY (USA)
15:50 – 17:20 Room A, B, Marquee and Cinema Corso		<b>SESSION 9 – AGGRESSIVE LYMPHOMAS</b> Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and E. Zucca, Bellinzona (Switzerland)
15:50	118	LONG-TERM SURVIVAL AND LOSS IN EXPECTANCY OF LIFE IN A POPULATION-BASED COHORT OF 7114 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA K.E. Smedby, Solna (Sweden)
16:05	119	R-CHOP +/-RADIOTHERAPY IN NON-BULKY LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FINAL RESULTS OF THE PROSPECTIVE RANDOMIZED PHASE III 02-03 TRIAL FROM THE LYSA/GOELAMS T. Lamy, Rennes (France)
16:20	120	RADIOTHERAPY TO BULKY DISEASE PET-NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF A PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL>60 STUDY OF THE DSHNHL M. Pfreundschuh, Homburg (Germany)
16:35	121	DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBL): A PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMoDL-B A.J. Davies, Southampton (UK)
16:50	122	PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY U. Vitolo, Turin (Italy)
17:05	123	RISK-ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF A MULTICENTER PROSPECTIVE PHASE II STUDY OF DA-EPOCH-R K. Dunleavy, Bethesda, MD (USA)
17:30 – 18:45 Marquee		<b>FAREWELL APERO</b>
Room A 18:30 – 19:30		ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND – IOSI <b>"THE BIG DEBATE: POINT COUNTER POINT"</b> <b>HAVE NEW DRUGS MADE STEM CELL TRANSPLANTATION OBSOLETE?</b> Chair: M. Ghilmini, Bellinzona (Switzerland) <i>Supported by Gilead Sciences Europe Ltd. who provided funding.</i>
Room B 18:45 – 20:45		KITE PHARMA <b>ENGINEERED T-CELL THERAPY: CAR-T'S ESTABLISHING A NEW PARADIGM OF TREATMENT IN RELAPSED AND REFRACTORY NHL?</b> Chair: G. Salles, Lyon (France) Co-chair: P. Dreger, Heidelberg (Germany)

■ Saturday, June 17, 2017

08:00 – 10:30  
Room 156  
(Lugano  
University)

**SPECIAL SESSION - CONTOURING IN MODERN LYMPHOMA  
RADIOTHERAPY PLANNING**

A.K. Berthelsen, Copenhagen (Denmark) and L. Specht,  
Copenhagen (Denmark)  
Organized by International Lymphoma Radiation Oncology  
Group - ILOG and  
European Society for Radiotherapy and Oncology – ESTRO  
**Compulsory pre-registration up to 30 attendees at  
registration@lymphcon.ch (fee CHF 50.-)**

08:30 – 10:00  
Room A

*2 parallel sessions*

**SESSION 10 – IMMUNOTHERAPIES**

Co-chairs: R. Levy, Stanford, CA (USA) and D.G. Maloney,  
Seattle, WA (USA)

08:30 124

CD27 STIMULATION ENHANCES CD20 MAB THERAPY  
THROUGH ACTIVATION OF INNATE IMMUNITY  
S.H. Lim, Southampton (UK)

08:45 125

NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL  
HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT:  
FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE PHASE 2  
CHECKMATE 205 TRIAL  
M. Fanale, Houston, TX (USA)

09:00 126

PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH  
PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA:  
SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY  
P.L. Zinzani, Bologna (Italy)

09:15 127

A PHASE Ib STUDY EVALUATING THE SAFETY AND  
CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED  
WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR  
REFRACTORY NON-HODGKIN LYMPHOMA (NHL)  
M.L. Palomba, New York, NY (USA)

09:30 128

HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE  
B-NHL TREATED WITH THE CD19-DIRECTED CAR T CELL  
PRODUCT JCAR017 (TRANSCEND NHL 001)  
J. Abramson, Boston, MA (USA)

09:45 129

A PHASE I TRIAL OF 19-28Z CAR-T CELLS POST-HIGH DOSE  
THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT-ASCT)  
FOR RELAPSED AND REFRACTORY (R/R) B-CELL NON-HODGKIN  
LYMPHOMA (B-NHL)  
C. Sauter, New York, NY (USA)

Room B

**SESSION 11 – MANTLE CELL LYMPHOMA**

Co-chairs: U. Novak, Bern (Switzerland) and G. Salles,  
Lyon (France)

08:30 130

P53 BUT NOT SOX11 IHC HAS PROGNOSTIC VALUE  
INDEPENDENT OF MIPI AND KI-67 IN PROSPECTIVE TRIALS OF  
THE EUROPEAN-MCL NETWORK  
M. Dreyling, Munich (Germany)



08:45 131

FIRST-LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR  
OR R-CHOP/R-CVP: RESULTS OF THE BRIGHT 5-YEAR  
FOLLOW-UP STUDY  
T. Hawkins, Auckland (New Zealand)

09:00 132

FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS  
HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND  
PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS;  
FINAL RESULTS OF A LYSA GROUP TRIAL  
R. Gressin, Grenoble (France)

09:15	133	IBRUTINIB-RITUXIMAB FOLLOWED BY REDUCED CHEMO-IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: A WINDOW OF OPPORTUNITY TO REDUCE CHEMO M.L. Wang, Houston, TX (USA)
09:30	134	IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY S. Rule, Plymouth (UK)
09:45	135	COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY C.S. Tam, Melbourne (Australia)
10:00 – 10:15		<b>BREAK</b>
10:15 – 11:15 Room A and B		<b>SESSION 12 – MARGINAL ZONE LYMPHOMA</b> Co-chairs: A. Lopez-Guillermo, Barcelona (Spain) and S. Montoto, London (UK)
10:15	136	INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION M. Frigeni, Pavia (Italy) <i>Travel Grant Winner (sponsored by Swiss Cancer Research Foundation)</i>
10:30	137	IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN A SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL) M. Herold, Erfurt (Germany)
10:45	138	LONG-TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT-2008-01) A. Salar, Barcelona (Spain)
11:00	139	PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA M. Coleman, New York, NY (USA)
11:15 – 11:40 Room A and B		<b>14-ICML HIGHLIGHTS</b>  "TAKE HOME MESSAGES" J.W. Friedberg, Rochester, NY (USA)
11:40 – 11:50		CLOSURE AND FAREWELL F. Cavalli, Bellinzona (Switzerland)
13:30 – 18:15 Room B		<b>WORKSHOP - NEW DEVELOPMENTS IN CANINE LYMPHOMA</b> Co-chairs: S. Comazzi, Milan (Italy), F. Gussetti, Zurich (Switzerland) and L. Marconato, Bologna (Italy) Organized by the European Canine Lymphoma Network <b>open to all 14-ICML attendees</b>

 This icon denotes presentations that will be available online, only for 14-ICML attendees, between July and September 2017, thanks to an unrestricted grant provided by  Bristol-Myers Squibb.

**NB:** Please note that this version of the program does not include changes communicated to 14-ICML Secretariat after May 25 (date of printing). You can find the definitive version at the ICML official website ([www.lymphcon.ch](http://www.lymphcon.ch)) and in the 14-ICML APP.

## 14-ICML TRANSPORT SERVICE

### Ticino Public Transport

14-ICML Transport Info Desk is available in the Main Hall, with the same working hours as the Registration desk.

- ▶ 14-ICML attendees who booked their accommodation in Ticino (the region where Lugano is the main town) will receive UPON HOTEL CHECK IN "Ticino Ticket", a public transport ticket, valid for the length of their stay, valid on all the public transports in Ticino.

An OneWay Ticket to reach booked hotels is available at the 14-ICML Transport Info Desk.

For further information on "Ticino Ticket" please visit <http://www.ticino.ch/en/ticket.html>

- ▶ 14-ICML attendees who did not book their accommodation in Ticino will receive a public transport ticket, valid from Tuesday 13 to Saturday 17, for all the public transports in Ticino AT THE 14-ICML TRANSPORT INFO DESK.

### 14-ICML Transport Service

For those hotels which are not in Ticino or are not very well served by public transports (and only for those who confirmed the hotel reservation through Amiconi Consulting), ICML Secretariat organize extra transports from hotel to convention center and vice versa.

The buses schedule and timetable is available at the ICML official website ([www.lymphcon.ch](http://www.lymphcon.ch)), on the 14-ICML APP and at the Transport Info Desk. The arrival / departure point is CAMPO MARZIO PARKING.

### Private Transports

Viale Cattaneo, the street connecting Lugano city center to Castagnola and running along Palazzo dei Congressi and Parco Ciani, is a two-way street.

During ICML, it will be **one way only** (direction: from city center to Castagnola) from Tuesday 13 to Friday 16 from 17:30 to 22:00 to permit private transport passenger boarding and alighting.

Outside this allowed time slot, Campo Marzio Parking is the passenger boarding and alighting appointed space.

### 14-ICML Shuttle Service

**A shuttle service connects the conference locations with the following timetable:**

- on Tuesday 13 from 18:30 to 21:30 (connecting Palazzo dei Congressi and Campo Marzio Parking only)
- from Wednesday 14 to Friday 16 from 07:30 to 11:00 and from 17:00 to 22:00 (connecting Palazzo dei Congressi, Campo Marzio Parking and Lugano University)
- on Saturday 17 from 07:30 to 10:30 (connecting Palazzo dei Congressi and Campo Marzio Parking only)

**Please note that, on this service, attendees with physical disabilities have precedence.**

### Further Information:


- Thursday 15 is bank holiday in Ticino and public transportation might run less frequently than on ordinary working days
- A cable railway connects Lugano Train Station to the center of the city, running daily from 07:00 to 19:00 (on Thursday 15 and Saturday 17 from 08:00 to 16:00 only)
- Lugano City Taxis are available outside the main entrance of Palazzo dei Congressi
- Lugano long lake will be closed to traffic on Friday 16 from 19:30.



The sign features a red and white logo at the top left, followed by the text "14-ICML 14th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA". Below this, the words "SHUTTLE BUS" are written in large, bold, red letters. Underneath, the locations "CAMPO MARZIO PARKING", "LUGANO UNIVERSITY", and "PALAZZO DEI CONGRESSI" are listed in black. At the bottom right, there is a black icon of a person in a wheelchair.

# 14-ICML CONTACTS

## Conference Secretariat



14-ICML Secretariat  
IOSI - Oncology Institute of Southern  
Switzerland  
Ospedale San Giovanni  
CH-6500 Bellinzona  
Tel. +41 91 922 05 75  
Fax +41 91 922 20 84  
Website: [www.lymphcon.ch](http://www.lymphcon.ch)

Foundation for the Research and Cure of  
Lymphoma in Ticino (Fondazione per la  
Ricerca e la Cura dei Linfomi nel Ticino)  
vat number: CHE-110.407.651 IVA  
IOSI - Oncology Institute of Southern  
Switzerland  
Ospedale San Giovanni  
CH-6500 Bellinzona  
[www.lymphcon.ch](http://www.lymphcon.ch)

ICML President:  
**Prof. Dr. Franco Cavalli**  
Tel: +41 91 811 86 66  
Fax: +41 91 811 80 56  
[franco.cavalli@eoc.ch](mailto:franco.cavalli@eoc.ch)

Chairman Local Organizing Committee:  
**Prof. Dr. Michele Ghielmini**  
Tel: +41 91 811 94 10  
Fax: +41 91 811 87 31  
[michele.ghiellini@eoc.ch](mailto:michele.ghiellini@eoc.ch)

**Cristiana Brentan**  
general coordination and information,  
scientific program, abstracts  
e-mail: [cristiana.brentan@lymphcon.ch](mailto:cristiana.brentan@lymphcon.ch)

**Orietta Lugli**  
exhibition management, satellite symposia,  
sponsorships, ancillary meetings  
e-mail: [orietta.lugli@lymphcon.ch](mailto:orietta.lugli@lymphcon.ch)

**Chiara Saporiti**  
Group and individual registrations,  
accounting  
e-mail: [registration@lymphcon.ch](mailto:registration@lymphcon.ch)

## 14-ICML Official Partners



**Eventmore**  
Via S. Gottardo 18D  
CH-6532 Castione

In charge of any technical aspect of conference  
sessions, satellite symposia and ancillary meetings  
held in Palazzo dei Congressi, Marquee Parco Ciani,  
University of Lugano, Cinema Corso and Villa Ciani

Tel: +41 (0)91 850 10 60  
Fax: +41 (0)91 850 10 61  
[info@eventmore.ch](mailto:info@eventmore.ch)  
[www.eventmore.ch](http://www.eventmore.ch)



In charge of hotel accommo-  
dation and "tours and guest's"  
program. Amicon Consulting can  
also provide the following ser-  
vices: meeting facilities (outside  
the Conference Venue), dinner  
reservations for groups, transfers  
services from/to the hotels/restau-  
rants and the conference centre.

**Amicon Consulting SA**  
Via al Forte 10  
CH - 6900 Lugano

Tel. +41 (0)91 921 38 12  
Fax +41 (0)91 921 38 13  
[info@amiconconsulting.ch](mailto:info@amiconconsulting.ch)  
[www.amiconconsulting.ch](http://www.amiconconsulting.ch)

# 15-ICML

15<sup>th</sup> International Conference on Malignant Lymphoma

Palazzo dei Congressi  
Lugano (Switzerland)  
[www.lymphcon.ch](http://www.lymphcon.ch)



**SAVE THE DATE: June 18-22, 2019**

# Keep looking

Shouldn't we strive to improve frontline treatment outcomes in patients with advanced-stage Hodgkin lymphoma?

- Current treatments have a failure rate of approximately 30%<sup>\*1-4</sup>
- Toxicities are unpredictable and, in some cases, fatal<sup>2-7</sup>
- Treatment can reduce patients' quality of life in the short and long term<sup>8,9</sup>

Until we solve these issues, we need to keep looking

\*28–36% of advanced-stage patients treated with ABVD will require additional therapy, progress, or die within 5 years<sup>1-4</sup>

Visit Booth 12 to find out more

References: 1. Gordon LI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). *J Clin Oncol*. 2013;31(6):684-691. 2. Carde P, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score  $\geq 3$ , high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup trial. *J Clin Oncol*. 2016;34(17):2028-2036. 3. Engert A, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. *J Clin Oncol*. 2009;27(27):4548-4554. 4. Viviani S, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. *N Engl J Med*. 2011;365(3):203-212. 5. Borchmann P, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. *J Clin Oncol*. 2011;29(32):4234-4242. 6. Duggan DB, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. *J Clin Oncol*. 2003;21(4):607-614. 7. Johnson P, McKenzie H. How I treat advanced classical Hodgkin lymphoma. *Blood*. 2015;125(11):1717-1723. 8. Khimani N, et al. Influence of new late effects on quality of life over time in Hodgkin lymphoma survivors: a longitudinal survey study. *Ann Oncol*. 2013;24(1):226-230. 9. Ganz PA, et al. Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. *J Clin Oncol*. 2003;21(18):3512-3519.

Takeda Oncology is a trademark of Takeda Pharmaceutical Company Limited. Millennium Pharmaceuticals, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.